<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-128647</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effectiveness and tolerability of levetiracetam in 43 children and adolescent with epilepsy</dc:title>
<dc:description xml:lang="en">Introduction. Levetiracetam (LEV) is the latest antiepileptic drug (AED) to be marketed, and is indicated for use in association in adults with focal seizures. Aims. The purpose of this study is to report on our experience of administering LEV to children and adolescents with pharmacoresistant epilepsies. Patients and methods. Retrospective open trial involving the observation of 43 children and adolescents with refractory epilepsies, using associated LEV for more than 6 months on an individual basis, the aim of which was to evaluate the repercussions on the frequency of the seizures, together with the adverse and beneficial side effects of LEV administration. Results. With mean doses of LEV of 45.01 ± 33.02 mg/kg/day the frequency of seizures was reduced by &gt; 50% in 65% of patients, while seizures were completely eradicated in 14% of patients; adverse side effects were reported in 28% of patients, although these were usually transient or tolerable, as LEV administration only had to be stopped for this reason in two cases (4.65%). Relatives noted an improvement in social behaviour and in cognitive skills in the case of 15 children (34.9%). Conclusions. 1. LEV is an effective drug that is well tolerated in children and adolescents with refractory epilepsies; 2. Its effectiveness in different types of seizures suggests a broad therapeutic spectrum; 3. LEV is a well tolerated drug with favourable side effects, a fact that is rarely reported with regard to other AED (AU)</dc:description>
<dc:creator>Herranz, JL</dc:creator>
<dc:creator>Rufo Campos, M</dc:creator>
<dc:creator>Arteaga, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. El levetiracetam (LEV) es el último fármaco antiepiléptico (FAE) comercializado, con la indicación para su empleo, en asociación, en adultos con crisis focales. Objetivo. Referir nuestra experiencia al administrar LEV a niños y adolescentes con epilepsias farmacorresistentes. Pacientes y métodos. Estudio abierto, de observación, retrospectivo, de 43 niños y adolescentes con epilepsias refractarias, con LEV asociado durante más de seis meses de manera individualizada, y con la valoración de la repercusión en la frecuencia de las crisis y los efectos secundarios adversos y favorables relacionados con LEV. Resultados. Con dosis medias de LEV de 45,01 ± 33,02 mg/kg/día se ha reducido en más de un 50% la frecuencia de crisis en un 65% de los pacientes, y se han suprimido las crisis en el 14% . Se han referido efectos adversos en un 28% de pacientes, habitualmente transitorios o tolerables, porque sólo tuvo que suprimirse el LEV en dos casos por este motivo (4,65%). En 15 niños (34,9%) los familiares apreciaron mejoría de la conducta social y de las habilidades cognitivas. Conclusiones. a) El LEV es un fármaco eficaz y bien tolerado en niños y adolescentes con epilepsias refractarias; b) su eficacia en diversos tipos de crisis sugiere un espectro terapéutico amplio, y c) el LEV es un fármaco muy bien tolerado, y con efectos secundarios favorables, circunstancia raramente referida con otros FAE (AU)</dc:description>
<dc:source>Rev Neurol;37(11): 1005-1008, dic. 2003. tab, graf</dc:source>
<dc:identifier>ibc-128647</dc:identifier>
<dc:title xml:lang="es">Eficacia y tolerabilidad del levetiracetam en 43 niños y adolescentes con epilepsia</dc:title>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d4420</dc:subject>
<dc:subject>^d22164^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29770</dc:subject>
<dc:subject>^d934^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d4907^s22012</dc:subject>
<dc:subject>^d4907^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>200312</dc:date>
</metadata>
</record>
</ibecs-document>
